Federated Hermes’s Royalty Pharma RPRX Stock Holding History

Federated Hermes’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$134K	Sell	2,800 -700	-20%	-$30.7K	﹤0.01%	1549
2025 Q4	$135K	Hold	3,500	–	–	﹤0.01%	1548
2025 Q3	$123K	Hold	3,500	–	–	﹤0.01%	1555
2025 Q2	$126K	Hold	3,500	–	–	﹤0.01%	1561
2025 Q1	$109K	Sell	3,500 -3,500	-50%	-$111K	﹤0.01%	1576
2024 Q4	$179K	Hold	7,000	–	–	﹤0.01%	1497
2024 Q3	$198K	Hold	7,000	–	–	﹤0.01%	1484
2024 Q2	$185K	Sell	7,000 -2,000	-22%	-$55.4K	﹤0.01%	1493
2024 Q1	$273K	Sell	9,000 -3,000	-25%	-$88.4K	﹤0.01%	1436
2023 Q4	$337K	Sell	12,000 -8,000	-40%	-$220K	﹤0.01%	1428
2023 Q3	$543K	Buy	20,000 +8,000	+67%	+$238K	﹤0.01%	1306
2023 Q2	$369K	Hold	12,000	–	–	﹤0.01%	1457
2023 Q1	$432K	Hold	12,000	–	–	﹤0.01%	1445
2022 Q4	$474K	Buy	+12,000	New	+$501K	﹤0.01%	1382
2021 Q1	–	Sell	-7,822	Closed	-$391K	–	2334
2020 Q4	$391K	Buy	+7,822	New	+$332K	﹤0.01%	1583

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Federated Hermes's RPRX Position: Q1 2026 in Review

Federated Hermes reduced its Royalty Pharma (RPRX) stake by 20% in Q1 2026, selling an estimated $30.7K and leaving 2,800 shares worth $134K. The position accounts for ﹤0.01% of the portfolio, ranked #1549.

Federated Hermes first reported a position in RPRX in Q4 2020 and has held it in 15 quarters since. The position peaked at $543K in Q3 2023. 588 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

Federated Hermes held 2,800 shares of Royalty Pharma worth $134K as of Q1 2026.
Federated Hermes sold 700 Royalty Pharma shares in Q1 2026, an estimated $30.7K.
Royalty Pharma made up ﹤0.01% of Federated Hermes's portfolio in Q1 2026, its #1549 holding.
Federated Hermes first reported a position in Royalty Pharma in Q4 2020 and has held it in 15 quarters since.
Federated Hermes's Royalty Pharma position peaked at $543K in Q3 2023.
588 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.